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Background: Mycoplasma hominis and Ureaplasma urealyticum are important opportunistic
pathogens implicated in urogenital infections and complicated pregnancy. We aimed to study
the role of these pathogens in symptomatic and asymptomatic pregnant women and determine
their clinical significance and antibiotic susceptibility.
Methods: One hundred pregnant women were included in the study, 50 symptomatic patients and
50 asymptomatic controls. Duplicate endocervical samples were taken from each individual and
analyzed using the Mycoplasma IST-2 kit and A7 agar medium. Antimicrobial susceptibility was
tested against doxycycline, josamycin, ofloxacin, erythromycin, tetracycline, ciprofloxacin,
azithromycin, clarithromycin, and pristinamycin using the Mycoplasma IST-2 kit.
Results: Twelve symptomatic pregnant women had spontaneous abortions. Of these, eight (66.7%)
cases had been colonized withM. hominis and/or U. urealyticum. Of the pregnant women infected
withM. hominis and/or U. urealyticum, 40.7% delivered a low birth weight infant.M. hominis was
successfully cultured in five women (5%) and U. urealyticum in 27 (27%). Among positive cultures,
15.6% and 84.4% of isolates were M. hominis and U. urealyticum, respectively. M. hominis and U.
urealyticumwereuniformly susceptible todoxycycline, tetracycline, andpristinamycin,whichmay
be successfully used in the empirical therapy of infected individuals.
Conclusions: It can be concluded that genital colonizationwithM. hominis andU. urealyticummay
predispose to spontaneous abortion and low birth weight.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Fax: +90 422 3410036.
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Genital mycoplasmas represent a group of microorganisms
that are commonly found in the genitourinary tract of preg-Published by Elsevier Ltd. All rights reserved.
M. hominis and U. urealyticum in pregnant women e91nant and non-pregnant women. They have been associated
with various pathological conditions and intrauterine infec-
tions, including pyelonephritis, pelvic inflammatory disease,
chorioamnionitis, endometritis, and postpartum fever, lead-
ing to important complications such as preterm birth, low
birth weight, spontaneous abortion, stillbirth, premature
birth, infertility, and perinatal mortality.1—6 The genital
mycoplasmas that contribute most to these conditions are
Mycoplasma hominis and Ureaplasma urealyticum. They are
most commonly present in the genital tract of sexually active
women.7—9 Colonization values worldwide for M. hominis
range between 20% and 30% and for U. urealyticum range
between 60% and 80%.10 The prevalence of these organisms is
significantly associated with socioeconomic conditions, such
as poverty, and increasing number of sexual partners.8,10
They pose a serious medical threat to the mother during
gestation and to the fetus and neonate.8 The role of myco-
plasmas in the aetiopathogenesis of the urogenital system is
still the subject of controversy.11 Controversy regarding the
association of genital mycoplasmas with bacterial vaginosis
also exists; some investigators claim that there is a relation-
ship between the two,12 whereas others do not.13
Mycoplasmas lack a cell wall—the target of beta-lactam
antibiotics and vancomycin. Tetracyclines, macrolides, and
quinolones are the major antibiotics used in the treatment of
urogenital infections caused by mycoplasmas.8 However,
their therapeutic efficacy may be unpredictable due to
increasing resistance.14 The extent of resistance varies geo-
graphically according to different antimicrobial therapy poli-
cies and the history of prior antimicrobial exposure in
different populations.6,8
The aim of the present study was to detect the presence of
U. urealyticum and M. hominis in symptomatic and control
pregnant women, including an analysis by age group and
gestation period. The association of these mycoplasmas with
pregnancy complications and their antimicrobial susceptibil-
ity were also assessed.
Subjects and methods
One hundred pregnant women (50 symptomatic patients and
50 asymptomatic controls) were studied at outpatient visits
to the gynecology and obstetrics clinics of Turgut Ozal Med-
ical Center, Inonu University Hospital, Malatya, Turkey from
July 2006 to May 2007. A questionnaire was completed for
each woman, recording personal data, sexual history, symp-
toms, and other obstetric and gynecologic disorders. Babies
born weighing less than 2500 g were classified as low birth
weight infants according to the World Health Organization
criteria. The mean  standard deviation age of the patients
was 28.6  5.3 years (range 18—41 years) and of controls was
28.6  5.6 years (range 18—39 years). Enrolled subjects were
sexually active pregnant women with a gestation period of
36 weeks.
The patient group experienced symptoms of vaginitis,
abnormal vaginal discharge, and/or itching or burning in
the genital area. Controls were those attending routine
checkups and had none of the above symptoms. It was
stipulated that all women participating in the study should
not have taken any antimicrobial agent prior to sampling that
could affect the growth of mycoplasmas. Women who did not
meet the inclusion criteria were excluded from the study,hence they were not consecutive cases. The approval of the
Ethics Committee of Inonu University was obtained. All
women gave informed consent prior to enrolling.
M. hominis and U. urealyticum are not routinely detected
by conventional bacteriological methods. For this study a
commercial kit, Mycoplasma IST-2 (BioMerieux, Marcy
l’Etoile, France), was used according to the manufacturer’s
instructions. The kit contains strips that give information on
the presence or absence of M. hominis and U. urealyticum
and also provide additional information on antibiotic suscept-
ibility to doxycycline, josamycin, ofloxacin, erythromycin,
tetracycline, ciprofloxacin, azithromycin, clarithromycin,
and pristinamycin. In order to process specimens, two endo-
cervical swabs were obtained from each individual. These
were processed in the laboratory within 4 hours. One strip
was placed directly into R1 tubes (transport medium) and
subsequently delivered to the clinical laboratory for the
identification of both U. urealyticum and M. hominis and
to determine antimicrobial susceptibility. The other swab
was cultured on blood, chocolate, and Sabouraud dextrose
agars. A Gram stained smear was made. The presence of
other organisms, such as Gardnerella vaginalis, was assessed
according to Amsel’s criteria and conventional microbiologi-
cal techniques.15,16
Swabs in the R1 transport medium were processed accord-
ing to the manufacturer’s instructions. They were vortexed
rapidly, and 3 ml of R1 was used to rehydrate the lyophilized
growth medium R2 (provided in the Mycoplasma IST-2 kit). A
Mycoplasma IST strip, consisting of 22 wells, was then inocu-
lated with the rehydrated R2 growth medium (55 ml per well,
overlaid with two drops of mineral oil). From the R2 positive
tube, 0.1 ml was also inoculated onto A7 Mycoplasma agar
plates (BioMerieux, Marcy l’Etoile, France) and incubated at
37 8C in an atmosphere of 5% CO2 for checking characteristic
colony morphology. All media and the inoculated strip were
incubated at 37 8C in a CO2 incubator and observed for color
changes, and the results were interpreted after 24 and 48 h
of incubation. Wells 1—5 provide information on the presence
or absence of M. hominis and U. urealyticum, with an
estimate of the density of each organism (104 CFU), and
wells 6—22 show the antimicrobial susceptibilities to doxy-
cycline, josamycin, ofloxacin, erythromycin, tetracycline,
ciprofloxacin, azithromycin, clarithromycin, and pristinamy-
cin. The A7 plates were examined with a microscope twice
daily for up to 5 days for characteristic colonies. Colonies
presenting with a fried egg appearance suggest the presence
of M. hominis, whereas colonies that are brown and tiny
indicate the presence of U. urealyticum. M. hominis ATCC
15488 and U. urealyticum ATCC 27813 strains were used as
controls.
Statistical analysis was performed using SPSS version 11.0
(SPSS Inc., Chicago, IL, USA). Categorical variables were
analyzed by Chi-square test. p-Values of <0.05 were con-
sidered statistically significant.
Results
Of the 100 subjects, 29 (29%) were positive for M. hominis
and/or U. urealyticum. Of these, 27 women were in the
patient group (54%) and two were in the control group (4%).
U. urealyticum was isolated alone from 22/50 (44%) patients
and 2/50 (4%) controls ( p < 0.05). The frequency of
Table 1 Prevalence of Mycoplasma hominis and Ureaplasma urealyticum among symptomatic and control women
Groupa U. urealyticum M. hominis U. urealyticum + M. hominis Total
Patients (N = 50) 22 (44%) 2 (4%) 3 (6%) 27 (54%)
Controls (N = 50) 2 (4%) 0 (0) 0 (0) 2 (4%)
Total 24 (24%) 2 (2%) 3 (3%) 29 (29%)
Results are n (%).
a p < 0.05.
e92 M.R. Bayraktar et al.M. hominis detected alone in the patient group was 2/50
(4%); no M. hominis was detected in controls. Three women
within the patient group (6%) were co-infected with both M.
hominis and U. urealyticum. Thus 32 M. hominis and U.
urealyticum were identified overall, 27 (84.4%) U. urealyti-
cum and five (15.6%) M. hominis (Table 1).
The distribution of M. hominis and U. urealyticum
according to age group is shown in Table 2. Of the sympto-
matic patients, six (12%) were aged 18—24 years, 12 (24%)
were aged 25—29 years, six (12%) were aged 30—34 years,
and three (6%) were over 35 years old. Significantly,
approximately two thirds of U. urealyticum and M. hominis
occurred in patients between the ages of 25 and 34 years
( p < 0.05).
The distribution ofM. hominis and U. urealyticum accord-
ing to gestation period is shown in Table 3. Of the 32Table 4 Numbers and percentages of pathological conditions ob
possible association with mycoplasmas
Patients (N = 50) Mycoplasma
Spontaneous abortion 12 (24%) 8 (29.6%)
Low birth weight 14 (28%) 11 (40.7%)
Still birth 3 (6%) 1 (3.7%)
Results are n (%).
Table 2 Distribution of Mycoplasma hominis and Urea-
plasma urealyticum in the different age groups
Age group (years) M. hominis U. urealyticum
18—24 1 (20%) 8 (29.6%)
25—29 3 (60%) 7 (25.9%)
30—34 1 (20%) 8 (29.6%)
35—39 0 (0) 3 (11.1%)
40 0 (0) 1 (3.7%)
Total 5 (100%) 27 (100%)
Results are n (%).
Table 3 Distribution of Mycoplasma hominis and Urea-
plasma urealyticum in the different gestation periods
Gestation period (weeks) M. hominis U. urealyticum
21—24 2 (40%) 1 (3.7%)
25—28 2 (40%) 6 (22.2%)
29—32 1 (20%) 7 (25.9%)
33—36 0 (0) 13 (48.1%)
Total 5 (100%) 27 (100%)
Results are n (%).mycoplasmas, 13 (48.1%) were seen in patients at between
33 and 36 weeks of gestation ( p < 0.05).
Twelve women in the patient group had a spontaneous
abortion at a gestation period of less than 36 weeks (Table 4).
Of these, eight (66.7%) cases had been colonized with M.
hominis and/or U. urealyticum and only three cases were
simultaneously infected with G. vaginalis. Other organisms
detected in the patient group are presented in Table 5. These
were as follows: G. vaginalis (seven strains, five in the
patient group and two in controls), beta-hemolytic strepto-
coccus (Streptococcus agalactiae; two strains, both in
patients), Candida albicans (22 strains, 12 in patients and
10 in controls), and 13 strains of other Candida species. Some
of the patients were co-infected with M. hominis and/or U.
urealyticum (11 cases) as follows: three (27.3%) with strains
of G. vaginalis, two (18.2%) with S. agalactiae, and six
(54.5%) with C. albicans (Table 5).
Among symptomatic patients with positive cervical myco-
plasmas, 11 (40.7%) were associated with low birth weight
(Table 4).
Antimicrobial susceptibilities were determined using the
Mycoplasma IST-2 kit and are shown in Tables 6 and 7. All
strains were susceptible to doxycycline, tetracycline, and
pristinamycin. Multiple resistance to two antibiotics was
rarely seen, even when mixed genital mycoplasmas were
present. Among M. hominis, the highest drug resistance rate
was 100% to erythromycin, while the highest drug resistance
rates in U. urealyticumwere 92.6% to ciprofloxacin and 85.2%
to ofloxacin. No resistance was observed to josamycin,
although some strains had intermediate resistance.
Discussion
In our study, 27 women (54%) in the patient group were
positive for M. hominis, U. urealyticum, or both mycoplas-
mas. In controls, twowomen (4%) yielded onlyU. urealyticum
( p < 0.05). None of the controls yielded M. hominis. Three
cases (6%) were infected with both M. hominis and U. urea-
lyticum. The highest prevalence of M. hominis and/or U.
urealyticum was seen in pregnant women in the 18—34 years
age group (Table 2). In comparing our findings with those ofserved in control and symptomatic pregnant women and their
s (N = 27) Controls (N = 50) Mycoplasmas (N = 2)
3 (6%) 0 (0)
13 (26%) 0 (0)
3 (6%) 0 (0)
Table 5 Co-infections of Mycoplasma hominis and/or Ureaplasma urealyticum with others pathogens
Pathogens Patients Controls Co-infection with mycoplasmas
in patients, n (%)
Gardnerella vaginalis (n = 7) 5 2 3 (27.3%)
Candida albicans (n = 22) 12 10 6 (54.5%)
Beta-hemolytic Streptococcus (n = 2) 2 0 2 (18.2%)
Total 19 12 11 (100%)
M. hominis and U. urealyticum in pregnant women e93many previous studies, which have reported between 10%
and 50% of women to be colonized with U. urealyticum but
colonization rates withM. hominis of less than 30%,11,12,17 we
found a distinct disproportion in the incidence of these two
mycoplasmas. U. urealyticum was more commonly detected
than M. hominis in both the patients and controls. Our
findings are fairly consistent with those of other studies
conducted in Poland9 and Greece,18 but distinctly different
to those of studies from the highlands of Papua NewGuinea,10
Portugal,11 and Japan.19
The presence of genital mycoplasmas is associated with an
increased risk of developing certain pathologic conditions of
pregnancy, such as spontaneous abortion, preterm labor, and
low birth weight.10,20 In the present study, 40.7% of pregnant
women infected with M. hominis and/or U. urealyticum
delivered a low birth weight infant. Moreover, eight out of
12 (66.7%) spontaneous abortion cases had been colonized
withM. hominis and/or U. urealyticum. Although, it has beenTable 6 Antimicrobial susceptibility of the total identified




Doxycycline 32 (100%) 0 (0) 0 (0)
Josamycin 29 (90.6%) 3 (9.4%) 0 (0)
Ofloxacin 4 (12.5%) 2 (6.3%) 26 (81.3%)
Erythromycin 16 (50%) 5 (15.6%) 11 (34.4%)
Tetracycline 32 (100%) 0 (0) 0 (0)
Ciprofloxacin 5 (15.6%) 0 (0) 27 (84.4%)
Azithromycin 17 (53.1%) 7 (21.9%) 8 (25%)
Clarithromycin 27 (84.4%) 1 (3.1%) 4 (12.5%)
Pristinamycin 32 (100%) 0 (0) 0 (0)
Results are n (%).
Table 7 Susceptibility of Mycoplasma hominis and Ureaplasma u
Antimicrobial agent M. hominis (n = 5)
S I R
Doxycycline 5 (100%) 0 (0) 0 (0
Josamycin 4 (80%) 1 (20%) 0 (0
Ofloxacin 1 (20%) 1 (20%) 3 (6
Erythromycin 0 (0) 0 (0) 5 (1
Tetracycline 5 (100%) 0 (0) 0 (0
Ciprofloxacin 3 (60%) 0 (0) 2 (4
Azithromycin 2 (40%) 1 (20%) 2 (4
Clarithromycin 3 (60%) 0 (0) 2 (4
Pristinamycin 5 (100%) 0 (0) 0 (0
S, susceptible; I, intermediate; R, resistant. Results are n (%).reported that U. urealyticum is associated with premature
onset of labor,19,21 the exact role of mycoplasmas in such
cases is not fully understood.
Simultaneous colonization with both M. hominis and U.
urealyticum was not common (6% in symptomatic patients),
but has been found to be as low as 2.92% in one population18
and as high as 60% in another.10 This discrepancymay be due to
variations in socioeconomic conditions and living standards.
A change in vaginal pH (e.g., bleeding in pregnancy, sexual
intercourse, or vaginal douching) may predispose to an over-
growth of potential pathogens.6,20,22 Both M. hominis and U.
urealyticum have been suggested to have an uncertain role in
bacterial vaginosis.2,23 As shown in Table 5, some potential
pathogens were frequently associated with mycoplasmas.
The exact reason for the simultaneous detection of these
potential pathogens remains unclear;8 it may be associated
with sexual activity, vaginal environment, sexual education,
socioeconomic status, poor hygiene, and altered immune
status.8,9 Urogenital diseases are not only caused by myco-
plasmas but also by other pathogens. It is usually impossible
to define which pathogen is responsible in mixed infections,
hence the antibiotic sensitivity of these pathogens must be
taken into account when empirical therapy is prescribed.2
Regarding antibiotic sensitivity, the results show that the
sensitivity to various antibiotics in U. urealyticum infection
was different from that of M. hominis infection. U. urealy-
ticum was more sensitive to macrolides and M. hominis was
more sensitive to quinolones. Antibiotics such as pristinamy-
cin (streptogramin group) and josamycin (a novel antibiotic
belonging to the newly developed macrolides), which are
unavailable in our local pharmacies and not prescribed in our
clinics, were tested in this study. They had potent activity
against both U. urealyticum and M. hominis. Although pris-
tinamycin, josamycin, doxycycline, and tetracycline resis-
tance has been reported for both U. urealyticum andrealyticum to nine different antimicrobials
U. urealyticum (n = 27)
S I R
) 27 (100%) 0 (0) 0 (0)
) 25 (92.6%) 2 (7.4%) 0 (0)
0%) 3 (11.1%) 1 (3.7%) 23 (85.2%)
00%) 16 (59.3%) 5 (18.5%) 6 (22.2%)
) 27 (100%) 0 (0) 0 (0)
0%) 2 (7.4%) 0 (0) 25 (92.6%)
0%) 15 (55.6%) 6 (22.2%) 6 (22.2%)
0%) 24 (88.9%) 1 (3.7%) 2 (7.4%)
) 27 (100%) 0 (0) 0 (0)
e94 M.R. Bayraktar et al.M. hominis,18 they were found to be the most active agents
against these pathogens in the current work, and could be
used in empirical therapy.M. hominis is naturally resistant to
erythromycin whereas U. urealyticum is moderately suscep-
tible to macrolides but is resistant to quinolones.14,24,25 The
significant difference related to susceptibility to macrolides
and quinolones has been reported before.26 Resistance to
quinolones such as ofloxacin and ciprofloxacin has been
observed in our clinical isolates of U. urealyticum. Higher
resistance of mycoplasmas to antimicrobials is due to muta-
tions in antibiotic targets and may suggest their relation to
higher pathogenicity.6,8,27
Empirical therapy is important in the treatment of myco-
plasmas since culture and identification methods are not
routinely used for the detection of mycoplasmas in Turkish
clinical laboratories. This is of paramount importance for
successful therapy and clinicians recommend early adminis-
tration of antibiotics for a good pregnancy outcome and to
prevent the occurrence of complications. However, limita-
tions of this study are the small number of samples and that
we could not investigate other potential pathogens such as
Ureaplasma parvum, since this was not available in the
commercial kit used in the present study.
Conclusions
This study shows a low prevalence of mycoplasmas in preg-
nant women in our population, since this population is gen-
erally conservative and there is mostly one sex partner. The
prevalence of genitourinary infections due to U. urealyticum
was considerably higher as compared toM. hominis infection.
The prevalence of U. urealyticum and M. hominis was sig-
nificantly correlated with age and gestation period. M.
hominis and U. urealyticum may be associated with sponta-
neous abortion and low birth weight. In inflammatory and
pathological states of pregnancy, testing for the presence of
mycoplasmas is necessary for a safe pregnancy outcome and
should be included in the diagnostic protocol. Our results also
indicate that doxycycline, tetracycline, and pristinamycin
are the first choice drugs when empirical therapy is required.
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